Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

Good grief. The best data released - recall we have been told next to nothing about B for c-has been all about preinfection NOT post infection. The trial will be in patients who are overwhelmingly infected with corona virus. They are sick enough to be hospitalized and that is very sick, as you know. RBL/LE has not shown us the data for benefit of B for c in such individuals. Their cells are full of virus and yet B works best before virus gets into cells. It is that simple.

We have yet to be shown data that convincingly argues that B can help hospitalized patients- and that is the trial.

A trial of prophylaxis would be excellent based on RBL data, but an IV drug for prophylaxis is a nonstarter.